Compare GERN & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | IVA |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | France |
| Employees | 229 | 77 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | GERN | IVA |
|---|---|---|
| Price | $1.47 | $5.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $2.17 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 14.8M | 355.4K |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | $751.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $2.94 |
| 52 Week High | $2.01 | $7.98 |
| Indicator | GERN | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 50.93 |
| Support Level | $1.44 | $4.90 |
| Resistance Level | $1.49 | $6.42 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 16.13 | 61.28 |
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.